LA
ESLA icon

Linden Advisors’s Estrella Immunopharma ESLA Stock Holding History

Linden Advisors’s Portfolio ESLA Stock Details ESLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-41,538
Closed -$418K – 579
2022
Q3 		$418K Hold
41,538
– – ﹤0.01% 435
2022
Q2 		$416K Sell
41,538
-123,876
-75% -$1.24M ﹤0.01% 464
2022
Q1 		$1.65M Hold
165,414
– – 0.01% 461
2021
Q4 		$1.64M Buy
+165,414
New +$1.64M 0.01% 458

Other funds holding ESLA

KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
HHGC
Hunting Hill Global Capital New York $129M AUM 17.34% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
SIA
SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return
LCM
Landscape Capital Management Englewood, New Jersey $1.58B AUM 26.88% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Linden Advisors's ESLA Position: Q4 2022 in Review

Linden Advisors sold out of Estrella Immunopharma (ESLA) in Q4 2022, closing a stake of 41,538 shares — an estimated $418K sold.

Linden Advisors first reported a position in ESLA in Q4 2021 and held it in 4 quarters. The position peaked at $1.65M in Q1 2022. 13 funds tracked by Wall St. Rank hold ESLA as of Q4 2022.

  • Linden Advisors reported no remaining Estrella Immunopharma position as of Q4 2022 after selling out during the quarter.
  • Linden Advisors sold 41,538 Estrella Immunopharma shares in Q4 2022, an estimated $418K.
  • Linden Advisors first reported a position in Estrella Immunopharma in Q4 2021 and held it in 4 quarters.
  • Linden Advisors's Estrella Immunopharma position peaked at $1.65M in Q1 2022.
  • 13 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q4 2022.

Based on Linden Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.